Ublituximab

• A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending
  2024-511168-10-00 Phase II 4 countries Kyverna Therapeutics Inc.
• Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS) Recruiting
  2025-522257-19-00 Phase II/III 2 countries Tg Therapeutics Inc.
• A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site… Recruiting
  2025-523757-33-00 Phase II 1 country Tg Therapeutics Inc.
• Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting
  2024-519284-18-00 Phase III 1 country Tg Therapeutics Inc.
• No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Recruiting
  2024-515470-26-00 Phase II 1 country Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici… Ended
  2025-521127-73-00 Phase III 4 countries Tg Therapeutics Inc.
• Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended
  2023-509555-13-00 Phase I 1 country Tg Therapeutics Inc.
• An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Ended
  2024-516680-91-00 Phase III 2 countries Tg Therapeutics Inc.

Showing 1–8 of 8 trials